title: Microflora Disturbance during Progression of Glucose Intolerance and Effect of Sitagliptin: An Animal Study.
abstract: Background. Emerging evidences have shown a close interplay between obesity, diabetes, and intestinal flora disturbance. Dipeptidyl peptidase-4 inhibitor, exemplified by sitagliptin, is highly efficacious in treating type 2 diabetes (T2DM), yet little is known if sitagliptin exerts beneficial effects on microbiota associated with obesity and T2DM. We evaluated changes of gut microbiota following the induction of obesity and T2DM in a streptozotocin treated high fat/high carbohydrate fed (HF/HC-STZ) rat model and explored the effect of sitagliptin on gut microbiota for HF/HC-STZ rats. Methods. Sitagliptin was administered via oral gavage to diabetic rats. Fecal DNA extraction and 454 pyrosequencing based on analysis of 16S rRNA genes was utilized to determine the overall structure of microbiota in fecal DNA samples. Results. Results showed that, at the level of phylum, there was higher abundance of Firmicutes and Tenericutes and less abundance of Bacteroidetes in obese rats compared to their lean counterparts. At the level of genus, short-chain fatty acid- (SCFA-) producing bacteria, Blautia, Roseburia, and Clostridium, and probiotics Lactobacillus, Bifidobacterium, and so forth were identified significantly different from each other among conditions. Conclusion. Marked shifts of the gut microbiota structure were observed in the rats during development of glucose intolerance. Intestinal flora changed in the process of glucose intolerance, and treatment of sitagliptin moderately corrected the dysbiosis of microbiota in T2DM.
authors.affiliation: Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
authors.forename: Xinfeng
authors.identifier: 0000-0003-2000-1628
authors.initials: X
authors.lastname: Yan
authors.affiliation: Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
authors.forename: Bo
authors.identifier: 0000-0003-1746-0399
authors.initials: B
authors.lastname: Feng
authors.affiliation: Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
authors.forename: Peicheng
authors.identifier: 0000-0002-2056-5506
authors.initials: P
authors.lastname: Li
authors.affiliation: Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
authors.forename: Zhaosheng
authors.identifier: 0000-0002-2398-4853
authors.initials: Z
authors.lastname: Tang
authors.affiliation: Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
authors.forename: Lin
authors.identifier: 0000-0001-8759-6211
authors.initials: L
authors.lastname: Wang
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000502:physiology; D048909:Diabetes Complications / Q000188:drug therapy / Q000382:microbiology*; D018450:Disease Progression; D000069196:Gastrointestinal Microbiome / Q000187:drug effects*; D018149:Glucose Intolerance / Q000188:drug therapy / Q000382:microbiology*; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D000068900:Sitagliptin Phosphate / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D000068900:Sitagliptin Phosphate